Akebia Therapeutics, Inc.
AKBA Nasdaq
SEC CIK 1517022
Follow Akebia Therapeutics
Weekly email: filings, results
Revenue, last quarter
$36.9M
−37.2% vs same quarter last year
Net income
−$14.4M
−2758.1% vs same quarter last year
EPS, diluted
−$0.05
Operating cash flow
$2.3M
−91.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $236.2M | −$5.3M |
| FY24 | $160.2M | −$69.4M |
| FY23 | $194.6M | −$51.9M |
| FY22 | $292.5M | −$94.2M |
| FY21 | $211.7M | −$282M |
| FY20 | $294.6M | −$384.8M |
| FY19 | $335M | −$279.7M |
| FY18 | $207.7M | −$143.6M |
| FY17 | $181.2M | −$73.7M |
| FY16 | $1.5M | −$135.7M |
| FY15 | $0 | −$60.7M |
| FY14 | $0 | −$37M |
| FY13 | - | −$13.2M |
| FY12 | - | −$8.2M |
| FY11 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 83.3% | 9.9% | −2.2% |
| FY24 | 60.6% | −31.5% | −43.3% |
| FY23 | 61.9% | −23.8% | −26.7% |
| FY22 | 70.7% | −27.6% | −32.2% |
| FY21 | 28.8% | −125% | −133.2% |
| FY20 | −0.6% | −128.2% | −130.6% |
| FY19 | 56.6% | −85.5% | −83.5% |
| FY18 | 96.3% | −85.8% | −69.1% |
| FY17 | - | −42.3% | −40.7% |
| FY16 | - | −8889.9% | −8843.5% |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $67.7M |
| FY24 | −$40.7M |
| FY23 | −$23.4M |
| FY22 | −$73.3M |
| FY21 | −$253M |
| FY20 | −$110.7M |
| FY19 | −$264.1M |
| FY18 | −$99.1M |
| FY17 | −$57.8M |
| FY16 | $55.2M |
| FY15 | −$52.8M |
| FY14 | −$27.7M |
| FY13 | −$11.4M |
| FY12 | - |
| FY11 | - |
- Akebia Therapeutics
- Healthcare median
Show the numbers
| Year | Akebia Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −2.2% | −30.6% |
| FY24 | −43.3% | −47% |
| FY23 | −26.7% | −58% |
| FY22 | −32.2% | −80.4% |
| FY21 | −133.2% | −71.8% |
| FY20 | −130.6% | −62.2% |
| FY19 | −83.5% | −46.2% |
| FY18 | −69.1% | −49.6% |
| FY17 | −40.7% | −45.9% |
| FY16 | −8843.5% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |